Up Regulation of Kai1 Gene Expression and Apoptosis Effect of Imatinib Mesylate in Gastric Adenocarcinoma (Ags) Cell Line Publisher



Shandiz SAS¹ ; Farasati S² ; Saeedi B² ; Baghbaniarani F² ; Asl EA³ ; Keshavarzpakseresht B² ; Rahimi A⁴ ; Assadi A⁵ ; Noorbazargan H⁶ ; Hesari MR⁷ ; Mirzaie A¹
Source: Asian Pacific Journal of Tropical Disease Published:2016

Abstract

Objective: To evaluate the effect of imatinib mesylate on KAI1 gene expression and apoptosis properties in human gastric carcinoma AGS cell line. Methods: Cell viability was assessed by MTT assay and quantitative real time PCR method was applied for investigation of Bax, Bcl-2, and KAI1 gene expression in AGS cells. The quantity of KAI1, Bax, and Bcl-compared to GAPDH gene expressions were examined using the formula 2-δδCt. Furthermore, cell apoptosis/necrosis was carried out by annexin V/PI staining and quantified with flow cytometry after treatment with imatinib. Results: Imatinib mesylate was showed to have a dose-dependent toxicity effect against AGS cells. KAI1/GAPDH gene expression ratios were 1.07 ± 0.02 (> 0.05), 1.68 ± 0.19 (> 0.05), 3.60 ± 0.55 (< 0.05), 6.54 ± 0.27 (< 0.001) for 20, 50, 80 and 100 μmol/L of imatinib concentrations. The mRNA levels of Bax detected by real-time PCR after treatment with imatinib mesylate were significantly increased. Also, the number of apoptotic cells was increased from 3.72% (statistically significant; P < 0.05) in untreated AGS cells to 21.72%, 83.04% and 85.80%, respectively, following treatment with 20, 40, and 60 μmol/L imatinib mesylate. Conclusions: The results suggest that imatinib mesylate can induce apoptosis pathway in a dose-dependent mode and might modulate metastasis by up regulating KAI1 gene expression in human gastric carcinoma AGS cell line. © 2016 Asian Pacific Tropical Medicine Press.